Animal anti-cancer drug
  • The companion animals grown at home were become a member of the family and the subject of care. Heavy investment in companion animals has increased the lifespan, but also increased the incidence of disease, such as decreased immunity, joint disease, skin change, tumor, and heart and hormone disorders with aging.

    It is cancer cells that normal cells do not function properly due to mutation or external factors, and do not die and grow continuously. The most terrible disease in human is probably cancer, but it cannot be an exception for a dog. As the lifespan of pet increases, the incidence of cancer is also increasing. 50% of dogs 10 years old or over die of cancer. The most common cancer deaths are malignant lymphoma, skin cancer, and mammary tumors,

    EAD200 is a natural peptide substance that represents a mechanism of action that reduces the phosphorylation of TGF-β1 induced Smad2. Administration of EAD200 alone to dogs diagnosed with many types of cancer has been shown to delay the growth of tumor.

    To maximize the anti-cancer effect of EAD200, we are investigating a combination with chemotherapy using paclitaxel. Although chemotherapy using paclitaxel causes tumor cell death, it also increases the expression of TGF-β1, which leads to rapid proliferation and metastasis of cancer cells, so more powerful chemotherapy should be used. After chemotherapy, inhibition of TGF-β1 by combination of EAD200, can effectively suppress tumor growth. When compared to paclitaxel alone, the combination of EAD200 showed low cell growth in cancer cell experiments. Because EAD200 is a drug based on the combination with paclitaxel, it is applicable to many cancers in which paclitaxel is used.